Related references
Note: Only part of the references are listed.Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes
M. J. Hassett et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Louis P. Garrison et al.
VALUE IN HEALTH (2019)
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
Ali Hajjar et al.
PLOS ONE (2019)
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Anne Julienne Genuino et al.
BMC HEALTH SERVICES RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Neelima Denduluri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rationale, Opportunities, and Reality of Biosimilar Medications
Gary H. Lyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
Caroline S. Clarke et al.
PLOS ONE (2017)
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer
Vakaramoko Diaby et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline
A. Eisen et al.
CURRENT ONCOLOGY (2015)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Sonya Blesser Streeter et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
How quickly do systematic reviews go out of date? A survival analysis
Kaveh G. Shojania et al.
ANNALS OF INTERNAL MEDICINE (2007)
Share Paper
